Abstracts tagged "arthritis and osteoporosis"

Abstract Number: 2210 • 2018 ACR/ARHP Annual Meeting
Effects of Anti-Citrullinated Peptide Antibody (ACPA) on Bone Microstructure in Rheumatoid Arthritis: A HR-pQCT Study
Ikuko Tanaka¹, Takashi Kato², Motokazu Kai³, Kunikazu Ogawa³, Hiroaki Mizuno¹, Mari Ushikubo⁴, Keisuke Izumi⁵, Hisaji Oshima⁶ and Shigenori Tamaki¹, ¹Nagoya Rheumatology Clinic, Nagoya, Japan, ²Department of Radiology, National Center for Geratrics and Gerontology, Obu, Japan, ³Mie Rheumatology Clinic, Suzuka, Japan, ⁴National Tokyo Medical Center, Tokyo, Japan, ⁵Department of connective Tissue Disease, National Tokyo Medical Center, Tokyo, Japan, ⁶Department of Connective Tissue Diseases, National Tokyo Medical Center, Tokyo, Japan
Background/Purpose: Rheumatoid arthritis (RA) induces systemic osteoporosis as well as osteoporotic change in the bones having arthritis by RA. Recently immune complex and anti-citrullinated peptide…
Abstract Number: 2345 • 2014 ACR/ARHP Annual Meeting
Anti-IL-6 Receptor Antibody Prevents Deterioration in Bone Structure in a Mouse Model of Collagen-Induced Arthritis
Hiroto Yoshida, Mika Yagoto, Miho Suzuki, Keisuke Tanaka, Misato Hashizume and Yoshihiro Matsumoto, Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan
Background/Purpose: Rheumatoid arthritis (RA) is a disease that typically induces secondary osteoporosis, which increases the risk of bone fractures and, consequently, mortality. Bone fracture is…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].